Drug intelligence / Profile preview

olmesartan medoxomil + probenecid

Development stage: Preclinical
Lead developer: Daiichi Sankyo
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of olmesartan medoxomil, an angiotensin II receptor antagonist used for treating hypertension, and probenecid, a hypouricemic agent used for treating hyperuricemia and gout. This is not a marketed combination product but represents a drug interaction. When co-administered, probenecid increases olmesartan exposure by 40-50% and may increase the occurrence of genitourinary side effects.

Targets

SLC22A8 (Organic anion transporter 3)AGTR1 (Angiotensin II Type-1 receptor)OAT1 (Organic anion transporter 1)

Beyond the preview

Go deeper on olmesartan medoxomil + probenecid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on olmesartan medoxomil + probenecid.

Explore the full profile